Low-Pressure Liquid Chromatography Market size was accounted for USD 6.5 billion in 2024 and is estimated to reach USD 14 billion by the end of 2037, expanding at a CAGR of 6.6% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of low-pressure liquid chromatography is evaluated at USD 6.9 billion.
Wide usage in purification and separation processes during drug development or clinical trials is a major influential factor in the LPLC market. The excellence in complex compounds encountered in industries such as pharmaceuticals and biotechnology has made chromatography techniques more attractive for pharma producers. Thus, they tend to invest in this sector to ensure better outputs for mass biologics manufacturing. For instance, in March 2023, AmbioPharm purchased the twin-column chromatography technology from YMC. The company aimed to utilize YMC’s proven disruptive purification solution for large-scale peptide production.
Further, the exponential growth of the biopharma industry signifies the increased involvement of low-pressure liquid chromatography (LPLC) in development and purification processes. This is evidence of a higher adoption in the low-pressure liquid chromatography (LPLC) market. According to a prediction released by a leading laboratory supplier, Thermo Fisher, the global biopharmaceutical industry is projected to hold a value of USD 856.1 billion by 2030. It also forecasted the probable share of small and midsized companies in this industry to attain USD 22 billion in 2025, exhibiting a notable CAGR of 11.0%. In addition, the rising interest in the food & beverage industry to invest in this sector for assuring proper quality control is also igniting adoption.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.6% |
|
Base Year Market Size (2024) |
USD 6.5 billion |
|
Forecast Year Market Size (2037) |
USD 14 billion |
|
Regional Scope |
|
End user (Pharmaceutical Companies, Biotechnology Companies, Research Laboratories, Academic Institutions)
As per end users, the pharmaceutical companies segment is set to dominate low-pressure liquid chromatography market share of around 67.1% by the end of 2037. Increased R&D activities and popularity among these manufacturers stimulated engagement with advanced purification and separation techniques such as LPLC. Their plans to commence large production for biologics require a cost-effective detection solution to acquire products of optimum purity. Thus, one can find the relativity of this segment’s growth with the increment of biopharma economic output. According to a report issued by the International Federation of Pharmaceutical Manufacturers & Associations, the biopharmaceutical industry contributed USD 1,838 billion to the global GDP in 2022.
Component (Instruments, Consumables, Services)
In terms of components, the low-pressure liquid chromatography (LPLC) market is estimated to witness significant progress in the instruments segment by the end of 2037. This segment is driven by the rising awareness of the importance of having adequate infrastructure. This is further pushing laboratories and research institutions to invest heavily in this segment. In addition, ongoing advancement in these devices offers the utmost accuracy and time efficiency, attracting more consumers to invest in them. For instance, in October 2024, Agilent announced the commercial launch of the Infinity III LC System, setting new standards of efficiency and performance in liquid chromatography. This innovation features intelligent monitoring & guidance, advanced solvent-level sensing, and an integrated sample ID reader.
Our in-depth analysis of the global market includes the following segments:
|
End user |
|
|
Component |
|
North America Market Analysis
North America low-pressure liquid chromatography market is predicted to hold revenue share of over 47.1% by the end of 2037. The fluent and frequent laboratory operations and upgrades in this region are a few of the major influencing factors. The trend of producing new biologics in the pharma industry of this region needs continuous and cost-effective supplies. According to the Research Nester report, the next-generation biomanufacturing industry in North America is predicted to dominate the global landscape with a share of 36.0% by 2037. Thus, pharma companies are heavily investing in LPLC to conduct uninterrupted drug development and production in an affordable manner.
The U.S. is positioning itself at the forefront of the low-pressure liquid chromatography market due to the presence of research-based biologic producers. These companies cultivate a notable part of the national economy, making them the backbone of this sector. According to the National and State Estimates, published in March 2022, the U.S. biopharmaceutical industry allocated USD 720.0 billion in the national value-added economy. The report further stated that it was a major 49.9% contributor to the total domestic medical and health-related R&D investment in 2020, accounting for USD 122.2 billion.
Canada is fostering a great environment of investment for global leaders in the low-pressure liquid chromatography market, backed by government-issued regulatory and financial support. The initiatives taken by the healthcare authorities of the country are remarkably influencing them to participate in this emerging scenario. According to a report published by the Northern University of Canada, in August 2024, the government of Ontario released a fund of USD 40 million in June 2024. It aimed to push local life sciences companies and biomanufacturers for globalization. The report further revealed that the global companies in this industry already invested USD 4 billion in Ontario over the last three-and-a-half years.
APAC Market Statistics
Asia Pacific is expected to register the fastest CAGR in the low-pressure liquid chromatography market during the forecast period. The region’s strong emphasis on the diverse pharmaceutical industry, particularly bio-based is a key influencer of the sector. According to a Research Nester report, the pharmaceutical microbiology industry of APAC is projected to hold a 28% share of total global revenue. Their non-stop activities and participation in drug discoveries and clinical trials are evidence of the rising need for effective laboratory solutions such as LPLC. Due to the high tendency to choose affordable solutions, particularly in price-sensitive countries, this sector has a great scope of generating profitable revenues.
India is accumulating resources from the low-pressure liquid chromatography market to leverage domestic production of biological products. The supportive government body of this country has played a crucial role in bringing advanced laboratory technologies including LPLC to accelerate its progress in biopharma. According to IBEF data, released in April 2023, the biopharmaceutical segment occupied a 49% share of the total bioeconomy industry in India in 2021, accounting for USD 39.4 billion. It further stated that the therapeutic components of this segment were valued at USD 10.3 billion in 2022.
China presents a lucrative opportunity for global leaders in the low-pressure liquid chromatography market to expand their territory in such a large marketplace. The greater manufacturing force of this country is pushing the country to acquire quality control assessments to set new standards of quality in the healthcare industry. According to the NLM report, published in August 2022, the total sale value of biological products in China was USD 4.1 billion in 2019, which further doubled to USD 9.2 billion in 2020. The report also evaluated the increased R&D expenditure, reaching USD 800.9 million in 2020.
Despite the fragmentation due to the high competition with HPLC and other advanced liquid reparation methods, this sector is still fulfilling global leaders with profitable revenues. It is further encouraging more companies to participate in these types of chromatology segments. Many are now making strategic capital investments to outstretch their portfolio toward emerging medical categories including LCs. For instance, in February 2022, Sartorius acquired the chromatography division of Novasep after getting approval from the FDA. With this acquisition, the company aimed to possess remarkable sales channels, such as USD 41.4 million gained by Novasep in 2020 and its wide consumer network in emerging low-pressure liquid chromatography (LPLC) markets such as the U.S., China, and India. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?